Search Results - "Mishriky, Basem M."

Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials by Okunrintemi, Victor, Mishriky, Basem M., Powell, James R., Cummings, Doyle M.

“…Dapagliflozin is a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor that has recently been shown to reduce the incidence of reported episodes of atrial…”
Get full text

A meta‐analysis of randomized controlled trials evaluating sodium‐glucose co‐transporter 2 inhibitors and incidental atrial fibrillation—Is there a true benefit? by Mishriky, Basem M., Cummings, Doyle M., Powell, James R.

Get full text

Transversus abdominis plane block for analgesia after Cesarean delivery: a systematic review and meta-analysis by Mishriky, Basem M., George, Ronald B., Habib, Ashraf S.

“…Purpose To assess the efficacy of transversus abdominis plane (TAP) block in improving analgesia following Cesarean delivery (CD). Source We searched MEDLINE,…”
Get full text

The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis by Mishriky, Basem M, Cummings, Doyle M, Tanenberg, Robert J

“…Highlights • Meta-analysis comparing DPP-4 inhibitors vs. Sulfonylureas added to metformin. • Sulfonylureas lower HbA1c more early; this difference is lost at…”
Get full text

GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials by Hamedi, Zahra, Mishriky, Basem M., Okunrintemi, Victor, Powell, James R., Cummings, Doyle M.

Get full text

Diabetes-Related Microvascular Complications – A Practical Approach by Mishriky, Basem M., Cummings, Doyle M., Powell, James R.

“…Diabetes-related microvascular complications include diabetic neuropathy (eg, diabetic symmetric polyneuropathy (DSPN), cardiac autonomic neuropathy,…”
Get full text

Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis by Mishriky, Basem M., Powell, James R., Wittwer, Jennifer A., Chu, Jennifer X., Sewell, Kerry A., Wu, Qiang, Cummings, Doyle M.

“…Aims While recent cardiovascular safety trials (CVST) concerning newer diabetes medications included mostly white participants, results are being generalized…”
Get full text

Nicotine for Postoperative Analgesia: A Systematic Review and Meta-Analysis by Mishriky, Basem M., Habib, Ashraf S.

“…BACKGROUND:The perioperative adminstration of nicotine has been investigated as an analgesic adjunct and a possible modality to prevent postoperative nausea…”
Get full text

102-LB: Cumulative Probability of Mortality among Non-Hispanic Black Compared with Non-Hispanic White Individuals with Type 2 Diabetes on Empagliflozin (EMPA-AA)—Real-World Data by MISHRIKY, BASEM M., CUMMINGS, DOYLE M., FU, YUANYUAN, HALLADAY, JACQUIE, JONES, WILLIAM S., BOAN, ANDREA D., JONES BERKELEY, SARA, PATIL, SHIVAJIRAO P., POWELL, JAMES R., ADAMS, ALYSSA, IRISH, WILLIAM

“…Authors 1, 2 & 11 participated equally. Given the underrepresentation of minorities in the CV outcome trials, guidelines encouraged investigating…”
Get full text

Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data by Mishriky, Basem M., Cummings, Doyle M., Fu, Yuanyuan, Halladay, Jacqueline R., Jones, Schuyler, Boan, Andrea D., Jones, Sara, Patil, Shivajirao P., Powell, James R., Adams, Alyssa, Irish, William

“…Aim There are limited data to evaluate hospitalization for heart failure (hHF) in non‐Hispanic Black (hereafter Black) or non‐Hispanic White (hereafter White)…”
Get full text

The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials by Younes, Ahmed M., Mishriky, Basem M., Powell, James R, Cummings, Doyle M

“…•There may be hesitancy in prescribing GLP-1RA in older adults.•GLP-1RAs were associated with lower incidence of MACE regardless of baseline age.•GLP-1RAs…”
Get full text

Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes by Mishriky, Basem M., Cummings, Doyle M., Powell, James R.

“…Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender…”
Get full text

20-LB: Heart Failure Hospitalization among African American Compared with White Individuals with Type 2 Diabetes on Empagliflozin—Real-World Data by MISHRIKY, BASEM M., CUMMINGS, DOYLE M., FU, YUANYUAN, HALLADAY, JACQUIE, JONES, WILLIAM S., BOAN, ANDREA, BERKELEY, SARA JONES, PATIL, SHIVAJIRAO P., POWELL, JAMES R., ADAMS, ALYSSA, IRISH, WILLIAM

“…While African Americans (AA) were underrepresented in the SGLT2i CVOT, the results from those trials were generalized to all, regardless of race. Our goal was…”
Get full text

2390-PUB: A Diabetes Clinic in the Primary Care Setting: A Quality Improvement Initiative in a Teaching Institution—One-Year Data by MISHRIKY, BASEM M., POWELL, JAMES R., HOLOMAN, CARYL E., MIAN, MUNA R.

“…Diabetes remains one of the most common chronic conditions seen in primary care clinics. While it remains one of the toughest quality measures to fulfill, it…”
Get full text

2365-PUB: Can Baseline Hemoglobin A1c Help Guide Treatment with an SGLT2i vs. DPP-4i? A Meta-analysis by PAGE, STEPHANIE O., MISHRIKY, BASEM M., UHRIG, JARROD, SEWELL, KERRY, MIAN, MUNA R., POWELL, JAMES R., CUMMINGS, DOYLE M.

“…Both sodium glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are effective drugs known to reduce hemoglobin A1c…”
Get full text

2363-PUB: The Efficacy of Low vs. High FDA-Approved SGLT2 Inhibitor Dose Compared with DPP-4 Inhibitors: A Meta-analysis by UHRIG, JARROD, MISHRIKY, BASEM M., PAGE, STEPHANIE O., SEWELL, KERRY, POWELL, JAMES R., PATIL, SHIVAJIRAO P., CUMMINGS, DOYLE M.

“…All FDA-approved SGLT2 inhibitors (SGLT2i) are currently available in two doses. While most SGLT2i have demonstrated CV benefit, there may be a difference in…”
Get full text

242-OR: Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African-American Patients with Type 2 Diabetes? A Meta-analysis by MISHRIKY, BASEM M., POWELL, JAMES R., WITTWER, JENNIFER A., CHU, JENNIFER X., SEWELL, KERRY, WU, QIANG, CUMMINGS, DOYLE M.

“…While patients enrolled in the cardiovascular safety trials (CVST) for GLP-1RA and SGLT2i were mostly whites, the ADA’s updated recommendations are being…”
Get full text

THE NEW FACE OF DIABETIC KETOACIDOSIS by Tanenberg, Robert J, Mishriky, Basem M

Get more information

Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality by Mendez, Carlos E., Walker, Rebekah J., Eiler, Christian R., Mishriky, Basem M., Egede, Leonard E.

“…Objective: To investigate the relationship between insulin use and clinical outcomes in patients with type 2 diabetes stratified by level of insulin resistance…”
Get full text

Re-examining insulin compared to non-insulin therapies for type 2 diabetes: when in the disease trajectory is insulin preferable? by Mishriky, Basem M., Cummings, Doyle M., Tanenberg, Robert, Pories, Walter J.

“…In patients with type 2 diabetes secondary to excess nutrients and energy balance, relative - not absolute - insulin deficiency plays a key role in disease…”
Get full text